524 related articles for article (PubMed ID: 34177796)
1. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Euh W; Lim S; Kim JW
Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
Ogawa Y; Nakahara T; Ando Y; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Murakami E; Kawaoka T; Miki D; Yamauchi M; Tsuge M; Imamura M; Oka S
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):989-996. PubMed ID: 37395206
[TBL] [Abstract][Full Text] [Related]
3. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease.
Kontana A; Tziomalos K
World J Gastroenterol; 2019 Jul; 25(28):3664-3668. PubMed ID: 31391764
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
Bajaj HS; Brown RE; Bhullar L; Sohi N; Kalra S; Aronson R
Diabetes Metab; 2018 Dec; 44(6):493-499. PubMed ID: 30149145
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.
Wong C; Yaow CYL; Ng CH; Chin YH; Low YF; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2020; 11():609135. PubMed ID: 33643221
[TBL] [Abstract][Full Text] [Related]
6. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
[TBL] [Abstract][Full Text] [Related]
7. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
Tian F; Zheng Z; Zhang D; He S; Shen J
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study.
Kim J; Han K; Kim B; Baek KH; Song KH; Kim MK; Kwon HS
Diabetes Res Clin Pract; 2022 Dec; 194():110187. PubMed ID: 36442545
[TBL] [Abstract][Full Text] [Related]
10. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
11. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
12. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
[TBL] [Abstract][Full Text] [Related]
13. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
14. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
[TBL] [Abstract][Full Text] [Related]
15. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology.
Akuta N; Kawamura Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
Intern Med; 2020 Aug; 59(16):1931-1937. PubMed ID: 32448832
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
18. Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study.
Bañares J; Manzano-Nuñez R; Prió A; Rivera-Esteban J; Camps-Relats L; Villarejo A; Ruiz-Ortega L; Pons M; Ciudin A; Salcedo MT; Vargas V; Genescà J; Pericàs JM
Front Endocrinol (Lausanne); 2022; 13():945626. PubMed ID: 36093073
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Dougherty JA; Guirguis E; Thornby KA
Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
